Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
76 studies found for:    "Ebola virus disease"
Show Display Options
Rank Status Study
1 Completed Efficacy of Favipiravir Against Severe Ebola Virus Disease
Condition: Ebola Virus Disease
Interventions: Other: WHO-recommended therapies;   Drug: Favipiravir
2 Recruiting PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Condition: Ebola Virus Disease
Intervention:
3 Unknown  Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
4 Recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
5 Enrolling by invitation A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
Condition: Acute Ebola Virus Disease
Intervention: Biological: INTERCEPT Plasma
6 Completed Efficacy of Favipiravir Against Ebola (JIKI)
Condition: Ebola Virus Disease
Intervention: Drug: Favipiravir
7 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
8 Completed A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
Condition: Ebola Virus Disease
Interventions: Biological: Low dose Ebola Zaire vaccine (Ad5-EBOV);   Biological: High dose Ebola Zaire vaccine (Ad5-EBOV);   Biological: placebo (one dose);   Biological: placebo (two doses)
9 Enrolling by invitation Persistence of the Immune Response After Ebola Vaccine Immunisation
Condition: Ebola Virus Disease
Intervention:
10 Unknown  Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
11 Completed Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
Condition: Ebola Virus Disease
Interventions: Biological: Ebola Vaccine - low dose;   Biological: Ebola Vaccine - mid dose;   Biological: Ebola Vaccine - high dose;   Biological: Placebo
12 Withdrawn Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)
Condition: Ebola Virus Disease
Interventions: Drug: Best Supportive Care;   Drug: Best Supportive Care + Amiodarone
13 Active, not recruiting A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV
Condition: Ebola Virus Disease
Interventions: Biological: ChAd3-EBO-Z;   Biological: Ad26.ZEBOV
14 Active, not recruiting A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
Condition: Ebola Virus Disease
Intervention: Biological: VSV-ZEBOV
15 Active, not recruiting Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Condition: Ebola Virus
Interventions: Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Drug: Placebo
16 Completed Evaluation of the FilmArray BioThreat-E Test
Condition: Ebola Virus Disease
Intervention:
17 Completed Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
Condition: Ebola
Interventions: Biological: Base Dose EBOV GP Vaccine;   Biological: 2x Base Dose EBOV GP Vaccine;   Biological: 4x Base Dose EBOV GP Vaccine;   Biological: 8x Base Dose EBOV GP Vaccine;   Biological: Placebo;   Biological: Matrix-M Adjuvant
18 Completed A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.
Condition: Ebola Virus Disease
Intervention: Biological: Ad5-EBOV
19 Withdrawn An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
Condition: Ebola Virus
Intervention: Drug: CMX001
20 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.